PPARGC1A

Across TCGA pan-cancer cohorts, PPARGC1A Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PPARGC1A data layer compared with 28 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PPARGC1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPARGC1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, THYM, and LUSC are the cancer types where PPARGC1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
THYM	OS	Median	All	0.068	0.977	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	17	view →
SARC	OS	Median	All	0.108	0.827	<.001	12	view →
BRCA	OS	Median	II,III,IV	0.238	0.567	.020	10	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	9	view →
PRAD	DFS	Median	All	0.448	0.888	<.001	8	view →
BLCA	DFS	Median	III,IV	0.074	0.495	<.001	6	view →
COAD	DFS	Median	III,IV	0.200	0.570	.003	6	view →
UCEC	DFS	Median	All	0.932	0.827	.035	4	view →
ESCA	DFS	Median	All	0.214	0.537	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PPARGC1A–ACC (DFS)

Open the ACC breakdown →